PTPN11 and prostate carcinoma: While inhibition of the PAR3/PAR6/aPKC complex may increase proliferation and survival of prostate cancer, PI3K-AKT and Ras activity can also be heightened by SHP-2 as previously described, which may also heavily influence prostate cancer dynamics (Table 3) [11,78,79,80,81].